Status:
COMPLETED
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Lead Sponsor:
Pfizer
Conditions:
Advanced Solid Tumors
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with...
Eligibility Criteria
Inclusion
- Advanced solid tumor malignancy ECOG 0 or 1
Exclusion
- Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior irradiation to ≥25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally located lung lesions unless recently treated with radiotherapy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00712504
Start Date
July 1 2004
End Date
November 1 2007
Last Update
November 11 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233-2115
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
4
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232